Cellectis shares fall 64.5% over the quarter and remain below their MM20
The Paris-listed biotech resumes its decline after the plunge that followed its nine-month results. The stock is trading in a bearish Paris market, while the company undergoes a strategic refocus toward in vivo genome editing.
A stock below its three moving averages, close to the €0.94 support
The Cellectis share loses 2.95% intraday, to €0.97, for a 7.66% decline over one week. The price is now below its MM20 (a gap of 7.57%), after the stock had rebounded in early November before running into resistance at €1.35.
The €0.94 support is about 3% from the current price: this is the level sellers have within reach.
The decline extends a very difficult quarter, with a 64.29% loss over three months, and the MACD remains in negative territory despite an improving histogram. The CAC 40 is down 0.99% at the same time, while the Nasdaq closed down 2.49% on Monday, amid a correction in artificial intelligence-related stocks.
Following nine-month results, cash runway announced through the second half of 2028
On November 13, Cellectis published nine-month results marked by a net loss of $101.1 million, compared with $41.3 million a year earlier. Among the risks cited on this occasion were the discontinuation of the lasme-cel and eti-cel clinical programs and a workforce reduction of up to 70% over 2026-2027.
On the pipeline side, the group expects preliminary data for HEAL-101 in the second half of 2027, following a Phase 1 trial in China, and its cash is expected to fund development through the second half of 2028.
Cellectis is listed in Paris (ordinary shares, eligible for the PEA French equity savings plan) and on the Nasdaq as ADSs, which explains why US trading sessions regularly weigh on the Paris line: the Nasdaq fell 2.49% on Monday.